{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1917","value":"-97.7850"},{"groupId":"OG001","spread":"0.1161","value":"-99.2637"},{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG002","spread":"NA","value":"-99.7472"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 0 hours post EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"103.7778","value":"324.2284"},{"groupId":"OG001","spread":"345.6173","value":"411.2175"},{"groupId":"OG002","spread":"82.9703","value":"165.9668"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG000","spread":"NA","value":"636.8307"},{"groupId":"OG001","spread":"520.3336","value":"770.4598"},{"groupId":"OG002","spread":"111.5861","value":"212.5270"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 3 Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG000","spread":"NA","value":"2164.2547"},{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG001","spread":"NA","value":"1311.2845"},{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG002","spread":"NA","value":"2513.913"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"90 Days Follow-Up: 90 days post EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"The pharmacodynamics (PD) activity of AZD8853 by assessment of candidate biomarkers in participants with selected advanced/metastatic solid tumors were assessed. This outcome measure was assessed only for substudy1 Part A.\n\nEnd of infusion= EOI; End of treatment= EOT","dispersionType":"Standard Deviation","groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"AZD8853 3000 mg"}],"paramType":"MEAN","populationDescription":"PD analysis set included all participants who received at least one dose of IP with at least one reportable concentration. Here, \"number of participants analyzed\" specifies all participants who were evaluated for this outcome measure and \"n\" (number analyzed in each raw) signifies the participants with available data that were analyzed for each timepoint for this outcome measure.","reportingStatus":"POSTED","timeFrame":"0 hours post EOI of Cycle 1 Day 1, Day 1 (Pre-dose) of Cycles 2 and 3 (each cycle equals to 21 days) and 90-days post EOT of 90 days follow-up","title":"Percentage Change From Baseline in Circulating Growth Differentiation Factor 15 (GDF15) Serum Levels","type":"SECONDARY","unitOfMeasure":"Percentage change from baseline in GDF15"}